Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 208235 | 4.4257 |
09:34 ET | 139016 | 4.5116 |
09:36 ET | 52622 | 4.5069 |
09:38 ET | 40971 | 4.37 |
09:39 ET | 40452 | 4.3 |
09:41 ET | 38963 | 4.34 |
09:43 ET | 64039 | 4.322 |
09:45 ET | 22628 | 4.32 |
09:48 ET | 52164 | 4.4433 |
09:50 ET | 40012 | 4.49 |
09:52 ET | 80264 | 4.535 |
09:54 ET | 41512 | 4.4895 |
09:56 ET | 37800 | 4.4 |
09:57 ET | 113323 | 4.375 |
09:59 ET | 24837 | 4.3516 |
10:01 ET | 23728 | 4.4 |
10:03 ET | 25963 | 4.405 |
10:06 ET | 13362 | 4.38 |
10:08 ET | 20889 | 4.395 |
10:10 ET | 13029 | 4.395 |
10:12 ET | 29960 | 4.37 |
10:14 ET | 10974 | 4.355 |
10:15 ET | 28793 | 4.3446 |
10:17 ET | 13507 | 4.38 |
10:19 ET | 20711 | 4.37 |
10:21 ET | 12231 | 4.34 |
10:24 ET | 16158 | 4.33 |
10:26 ET | 5972 | 4.345 |
10:28 ET | 87208 | 4.31 |
10:30 ET | 13615 | 4.304 |
10:32 ET | 16175 | 4.335 |
10:33 ET | 15897 | 4.375 |
10:35 ET | 144171 | 4.5125 |
10:37 ET | 23796 | 4.515 |
10:39 ET | 27302 | 4.5249 |
10:42 ET | 38874 | 4.565 |
10:44 ET | 67668 | 4.61 |
10:46 ET | 42441 | 4.545 |
10:48 ET | 70690 | 4.49 |
10:50 ET | 12947 | 4.49 |
10:51 ET | 11023 | 4.4936 |
10:53 ET | 9379 | 4.4905 |
10:55 ET | 48449 | 4.53 |
10:57 ET | 4239 | 4.4901 |
11:00 ET | 25803 | 4.5 |
11:02 ET | 13248 | 4.475 |
11:04 ET | 14011 | 4.475 |
11:06 ET | 2671 | 4.4794 |
11:08 ET | 37262 | 4.44 |
11:09 ET | 17036 | 4.42 |
11:11 ET | 10032 | 4.41 |
11:13 ET | 8772 | 4.405 |
11:15 ET | 58598 | 4.375 |
11:18 ET | 9069 | 4.37 |
11:20 ET | 9703 | 4.375 |
11:22 ET | 33013 | 4.39 |
11:24 ET | 5539 | 4.37 |
11:26 ET | 6943 | 4.375 |
11:27 ET | 16656 | 4.3999 |
11:29 ET | 3565 | 4.395 |
11:31 ET | 5774 | 4.385 |
11:33 ET | 1391 | 4.38 |
11:36 ET | 14618 | 4.375 |
11:38 ET | 5753 | 4.365 |
11:40 ET | 7313 | 4.355 |
11:42 ET | 20493 | 4.33 |
11:44 ET | 146627 | 4.3113 |
11:45 ET | 29308 | 4.305 |
11:47 ET | 43968 | 4.285 |
11:49 ET | 11510 | 4.2712 |
11:51 ET | 37449 | 4.26 |
11:54 ET | 10145 | 4.255 |
11:56 ET | 11435 | 4.265 |
11:58 ET | 21111 | 4.265 |
12:00 ET | 2450 | 4.2693 |
12:02 ET | 26743 | 4.265 |
12:03 ET | 2627 | 4.26 |
12:05 ET | 5693 | 4.255 |
12:07 ET | 100 | 4.255 |
12:09 ET | 11787 | 4.255 |
12:12 ET | 7467 | 4.2505 |
12:14 ET | 23430 | 4.25 |
12:16 ET | 12288 | 4.225 |
12:18 ET | 34429 | 4.235 |
12:20 ET | 34932 | 4.245 |
12:21 ET | 12394 | 4.235 |
12:23 ET | 24186 | 4.245 |
12:25 ET | 5690 | 4.235 |
12:27 ET | 425 | 4.235 |
12:30 ET | 8040 | 4.235 |
12:32 ET | 2847 | 4.23 |
12:34 ET | 28650 | 4.22 |
12:36 ET | 30673 | 4.245 |
12:38 ET | 3001 | 4.2431 |
12:39 ET | 5944 | 4.235 |
12:41 ET | 9229 | 4.225 |
12:43 ET | 3059 | 4.23 |
12:45 ET | 8474 | 4.22 |
12:48 ET | 5070 | 4.2225 |
12:50 ET | 34980 | 4.2352 |
12:52 ET | 3998 | 4.2203 |
12:54 ET | 26375 | 4.235 |
12:56 ET | 15170 | 4.255 |
12:57 ET | 700 | 4.25 |
12:59 ET | 1629 | 4.255 |
01:01 ET | 27467 | 4.23 |
01:03 ET | 3849 | 4.23 |
01:06 ET | 5109 | 4.23 |
01:08 ET | 5252 | 4.2389 |
01:10 ET | 925 | 4.23 |
01:12 ET | 3968 | 4.225 |
01:14 ET | 16357 | 4.24 |
01:15 ET | 16548 | 4.28 |
01:17 ET | 28957 | 4.265 |
01:19 ET | 2558 | 4.275 |
01:21 ET | 11676 | 4.24 |
01:24 ET | 3527 | 4.255 |
01:26 ET | 3049 | 4.235 |
01:28 ET | 3634 | 4.25 |
01:30 ET | 6719 | 4.265 |
01:32 ET | 2745 | 4.25 |
01:33 ET | 710 | 4.24 |
01:35 ET | 5778 | 4.23 |
01:37 ET | 101861 | 4.21 |
01:39 ET | 12295 | 4.19 |
01:42 ET | 5694 | 4.1999 |
01:44 ET | 10242 | 4.16 |
01:46 ET | 27013 | 4.155 |
01:48 ET | 18779 | 4.165 |
01:50 ET | 8195 | 4.19 |
01:51 ET | 3109 | 4.195 |
01:53 ET | 9303 | 4.17 |
01:55 ET | 40584 | 4.145 |
01:57 ET | 2439 | 4.14 |
02:00 ET | 7299 | 4.135 |
02:02 ET | 11740 | 4.135 |
02:04 ET | 4850 | 4.12 |
02:06 ET | 6218 | 4.12 |
02:08 ET | 2954 | 4.1152 |
02:09 ET | 11214 | 4.1001 |
02:11 ET | 828 | 4.105 |
02:13 ET | 1400 | 4.1 |
02:15 ET | 11772 | 4.105 |
02:18 ET | 13838 | 4.12 |
02:20 ET | 1500 | 4.12 |
02:22 ET | 2041 | 4.106 |
02:24 ET | 11031 | 4.115 |
02:26 ET | 826 | 4.11 |
02:27 ET | 18983 | 4.135 |
02:29 ET | 11818 | 4.1504 |
02:31 ET | 6315 | 4.13 |
02:33 ET | 8522 | 4.135 |
02:36 ET | 6312 | 4.13 |
02:38 ET | 500 | 4.13 |
02:40 ET | 952 | 4.125 |
02:42 ET | 1744 | 4.125 |
02:44 ET | 5373 | 4.125 |
02:45 ET | 2128 | 4.12 |
02:47 ET | 15468 | 4.15 |
02:49 ET | 3539 | 4.1629 |
02:51 ET | 2693 | 4.155 |
02:54 ET | 5476 | 4.17 |
02:56 ET | 2151 | 4.165 |
02:58 ET | 3147 | 4.1544 |
03:00 ET | 3535 | 4.16 |
03:02 ET | 4725 | 4.155 |
03:03 ET | 1544 | 4.135 |
03:05 ET | 2740 | 4.13 |
03:07 ET | 4810 | 4.12 |
03:09 ET | 3320 | 4.135 |
03:12 ET | 77234 | 4.15 |
03:14 ET | 4875 | 4.1391 |
03:16 ET | 14384 | 4.125 |
03:18 ET | 26994 | 4.135 |
03:20 ET | 2265 | 4.13 |
03:21 ET | 7415 | 4.14 |
03:23 ET | 6167 | 4.125 |
03:25 ET | 3231 | 4.12 |
03:27 ET | 4950 | 4.12 |
03:30 ET | 6345 | 4.12 |
03:32 ET | 23790 | 4.12 |
03:34 ET | 15128 | 4.135 |
03:36 ET | 17424 | 4.15 |
03:38 ET | 6324 | 4.1575 |
03:39 ET | 1740 | 4.15 |
03:41 ET | 17659 | 4.175 |
03:43 ET | 5435 | 4.175 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 2.6B | -2.7x | --- |
CG Oncology Inc | 2.7B | -41.3x | --- |
Celldex Therapeutics Inc | 2.7B | -14.4x | --- |
Rocket Pharmaceuticals Inc | 2.5B | -9.1x | --- |
Intellia Therapeutics Inc | 2.6B | -5.1x | --- |
Vera Therapeutics Inc | 2.4B | -19.1x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 701.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.22 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.